Loading…
AZTR
Azitra, Inc.
NYSE American· Healthcare· Biotechnology· CUSIP 05479L302
$0.18-4.79%Price as of Aug 29, 18:48 UTC · updated once a day, after the close
Key metrics
- Market cap
- $10.72M
- P/E
- 8.8x
- Forward P/E
- —
- P/B
- 1.5x
- Dividend yield
- —
- Payout
- —
- EPS
- $0.02
- ROE
- -256.67%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -1.18
- 52-week high
- $1.09
- 52-week low
- $0.10
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $0.26 | $2.84 | $184.00 | |
| P/S | — | — | 433.6x | 16.2x |
| P/B | 0.7x | 0.7x | 0.6x | 3.8x |
| EPS | -$2.25 | -$15.70 | -$366.17 | |
| Profit margin | — | — | -119566.56% | -1644.87% |
| ROE | -288.21% |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
$0.23
Square root of 22.5 × earnings × book value — the two ceilings Graham proposed. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$0.45
Median P/E of 22.4 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LNAILunai Bioworks Inc. | $2.37 | — | — | — | -325.46% | $10.75M |
| APREAprea Therapeutics, Inc. | $0.84 | — | 0.3x | — | -46.15% | $10.56M |
| GDTCCytoMed Therapeutics Ltd | $0.92 | — | 2.1x | — | -50.28% | $10.89M |
| MTVAMetaVia Inc. | $1.70 |
About the company
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
- 13
- Branford, United States
Company description provided by Yahoo Finance.